Literature DB >> 23121672

Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response.

L Fraccaroli1, E Grasso, V Hauk, M Cortelezzi, G Calo, C Pérez Leirós, R Ramhorst.   

Abstract

Successful embryo implantation occurs followed by a local inflammatory/T helper type 1 (Th1) response, subsequently redirected towards a tolerogenic predominant profile. The lack of control of this initial local inflammatory response may be an underlying cause of early pregnancy complications as recurrent spontaneous abortions (RSA). Considering that vasoactive intestinal peptide (VIP) mediates anti-inflammatory and tolerogenic effects in several conditions we hypothesized that VIP might contribute to tolerance towards trophoblast antigens during the early interaction of maternal leucocytes and trophoblast cells. In this study we investigated VIP/VPAC system activity and expression on maternal peripheral blood mononuclear cells (PBMCs) after interaction with immortalized trophoblast cells (Swan-71 cell line) as an in-vitro model of feto-maternal interaction, and we analysed whether it modulates maternal regulatory T cell (T(reg))/Th1 responses. We also investigated the contribution of the endogenous VIP/VPAC system to RSA pathogenesis. VIP decreased T-bet expression significantly, reduced monocyte chemotactic protein-1 (MCP-1) and nitrite production in co-cultures of PBMCs from fertile women with trophoblast cells; while it increased the frequency of CD4(+) CD25(+) forkhead box protein 3 (Foxp3)(+) cells, transforming growth factor (TGF)-β expression and interleukin (IL)-10 secretion. These effects were prevented by VIP-specific antagonist. Interestingly, PBMCs from RSA patients displayed significantly higher T-bet expression, lower T(reg) frequency and lower frequency of VIP-producer CD4 lymphocytes after the interaction with trophoblast cells. Moreover, the patients displayed a significantly lower frequency of endometrial CD4(+) VIP(+) cells in comparison with fertile women. VIP showed a Th1-limiting and T(reg) -promoting response in vitro that would favour early pregnancy outcome. Because RSA patients displayed defects in the VIP/VPAC system, this neuropeptide could be a promising candidate for diagnostic biomarker or surrogate biomarker for recurrent spontaneous abortions.
© 2012 British Society for Immunology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121672      PMCID: PMC3518891          DOI: 10.1111/j.1365-2249.2012.04668.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

Review 1.  Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy.

Authors:  Shigeru Saito; Akitoshi Nakashima; Tomoko Shima; Mika Ito
Journal:  Am J Reprod Immunol       Date:  2010-04-23       Impact factor: 3.886

2.  An investigation into the relative merits of pituitary adenylate cyclase-activating polypeptide (PACAP-27) and vasoactive intestinal polypeptide as vagal neuro-transmitters in exocrine pancreas of rats.

Authors:  S Wheeler; J E Eardley; K F McNulty; C P Sutcliffe; J D Morrison
Journal:  Exp Physiol       Date:  1997-07       Impact factor: 2.969

3.  A role for TLRs in the regulation of immune cell migration by first trimester trophoblast cells.

Authors:  Vikki M Abrahams; Irene Visintin; Paulomi B Aldo; Seth Guller; Roberto Romero; Gil Mor
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 4.  Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP.

Authors:  Catalina Abad; Rosa P Gomariz; James A Waschek
Journal:  Curr Top Med Chem       Date:  2006       Impact factor: 3.295

Review 5.  A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system.

Authors:  J C Warning; S A McCracken; J M Morris
Journal:  Reproduction       Date:  2011-03-09       Impact factor: 3.906

6.  Current clinical options for diagnosis and treatment of recurrent spontaneous abortion. Clinical Guidelines Recommendation Committee for Diagnosis and Treatment of Recurrent Spontaneous Abortion.

Authors:  C B Coulam; D A Clark; A E Beer; W H Kutteh; R Silver; J Kwak; M Stephenson
Journal:  Am J Reprod Immunol       Date:  1997-08       Impact factor: 3.886

7.  Effect of erythropoietin on staurosporine-induced apoptosis and differentiation of SH-SY5Y neuroblastoma cells.

Authors:  Nicolás Pregi; Daniela Vittori; Gladys Pérez; Claudia Pérez Leirós; Alcira Nesse
Journal:  Biochim Biophys Acta       Date:  2006-01-18

Review 8.  Neuropeptides: keeping the balance between pathogen immunity and immune tolerance.

Authors:  Elena Gonzalez-Rey; Doina Ganea; Mario Delgado
Journal:  Curr Opin Pharmacol       Date:  2010-08       Impact factor: 5.547

9.  Peripheral blood galectin-1-expressing T and natural killer cells in normal pregnancy and preeclampsia.

Authors:  Attila Molvarec; Sandra M Blois; Balázs Stenczer; Gergely Toldi; Irene Tirado-Gonzalez; Mika Ito; Tomoko Shima; Satoshi Yoneda; Barna Vásárhelyi; János Rigó; Shigeru Saito
Journal:  Clin Immunol       Date:  2011-02-02       Impact factor: 3.969

10.  Inhalable powder formulation of vasoactive intestinal peptide derivative, [R15,20,21, L17]-VIP-GRR, attenuated neutrophilic airway inflammation in cigarette smoke-exposed rats.

Authors:  Satomi Onoue; Shingen Misaka; Yosuke Aoki; Shin-ichiro Karaki; Atsukazu Kuwahara; Asami Ohide; Takahiro Mizumoto; Shizuo Yamada
Journal:  Eur J Pharm Sci       Date:  2010-08-24       Impact factor: 4.384

View more
  5 in total

1.  Effect of baicalein on the expression of VIP in extravillous cytotrophoblasts infected with human cytomegalovirus in vitro.

Authors:  Yuan Qiao; Jian-Guo Fang; Juan Xiao; Tao Liu; Jing Liu; Yan-Li Zhang; Su-Hua Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

2.  VIP boosts regulatory T cell induction by trophoblast cells in an in vitro model of trophoblast-maternal leukocyte interaction.

Authors:  Laura Fraccaroli; Esteban Grasso; Vanesa Hauk; Daniel Paparini; Elizabeth Soczewski; Gil Mor; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  J Leukoc Biol       Date:  2015-04-15       Impact factor: 6.011

3.  Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide.

Authors:  Jihad Georges Youssef; Mohammad Z Bitar; Faisal Zahiruddin; Mukhtar Al-Saadi; Mahmoud Elshawwaf; Simon Yau; Ahmad Goodarzi; Jonathan C Javitt
Journal:  Crit Care Explor       Date:  2022-01-05

4.  VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model.

Authors:  Lucila Gallino; Guillermina Calo; Vanesa Hauk; Laura Fraccaroli; Esteban Grasso; Mónica Vermeulen; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  Sci Rep       Date:  2016-01-06       Impact factor: 4.379

5.  VIP Promotes Recruitment of Tregs to the Uterine-Placental Interface During the Peri-Implantation Period to Sustain a Tolerogenic Microenvironment.

Authors:  Lucila Gallino; Vanesa Hauk; Laura Fernández; Elizabeth Soczewski; Soledad Gori; Esteban Grasso; Guillermina Calo; Nora Saraco; Esperanza Berensztein; James A Waschek; Claudia Pérez Leirós; Rosanna Ramhorst
Journal:  Front Immunol       Date:  2020-01-08       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.